ESMO News

Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC

noreply@esmo.org — Thu, 30 Apr 2026 07:04:00 +00:00

Findings from the Beamion LUNG-1 study

EMA Recommends Granting a Marketing Authorisation for Lurbinectedin

noreply@esmo.org — Thu, 30 Apr 2026 07:04:00 +00:00

It is indicated for the maintenance treatment of adult patients with extensive-stage small cell lung cancer

Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian

noreply@esmo.org — Wed, 29 Apr 2026 11:04:00 +00:00

This guide is now available in 15 different languages

EMA Recommends Extension of Indications for Inotuzumab Ozogamicin

noreply@esmo.org — Wed, 29 Apr 2026 07:04:00 +00:00

New indication concerns treatment of paediatric patients with CD22-positive B cell precursor ALL

Patient Guide in Bladder Cancer Now Available Also in French

noreply@esmo.org — Tue, 28 Apr 2026 13:04:00 +00:00

Expanding the guide’s availability in more languages

Datopotamab Deruxtecan Improves Survival Over Chemotherapy in Patients with Previously Untreated, Locally Recurrent Inoperable or Metastatic TNBC

noreply@esmo.org — Tue, 28 Apr 2026 07:04:00 +00:00

Findings from the TROPION-Breast02 study

Clinical Activity of Elraglusib with Gemcitabine Plus Nab-paclitaxel in First-Line Treatment of Patients with Metastatic Pancreatic Ductal Adenocarcinoma

noreply@esmo.org — Mon, 27 Apr 2026 07:04:00 +00:00

Findings from the phase II study

EMA Recommends Granting a Conditional Marketing Authorisation for Nadofaragene Firadenovec

noreply@esmo.org — Fri, 24 Apr 2026 08:04:00 +00:00

It is indicated for the treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ with or without papillary tumours

Pembrolizumab Plus Weekly Paclitaxel, With Or Without Bevacizumab, Improves OS in Patients With Platinum-Resistant Recurrent Ovarian Cancer

noreply@esmo.org — Thu, 23 Apr 2026 07:04:00 +00:00

Findings from the ENGOT-ov65/KEYNOTE-B96 study

EMA Recommends Extension of Indications for Serplulimab

noreply@esmo.org — Wed, 22 Apr 2026 07:04:00 +00:00

New indications concern the treatment of patients with oesophageal squamous cell carcinoma and non-small cell lung cancer

Adding Relacorilant to Nab-paclitaxel Prolongs OS in Patients with Platinum-Resistant Ovarian Cancer

noreply@esmo.org — Tue, 21 Apr 2026 07:04:00 +00:00

Findings from the ROSELLA study

Quadruplet Isa-KRd Regimen Improves NGS-MRD Negativity in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma

noreply@esmo.org — Mon, 20 Apr 2026 07:04:00 +00:00

Findings from the EMN24 IsKia study

EMA Recommends Granting a Marketing Authorisation for Tarlatamab

noreply@esmo.org — Fri, 17 Apr 2026 07:04:00 +00:00

It is indicated for the treatment of adult patients with extensive-stage SCLC

Transdermal Oestradiol Patches Non-inferior to LHRH Agonists Regarding Metastasis-Free Survival in Patients with Locally Advanced Prostate Cancer

noreply@esmo.org — Thu, 16 Apr 2026 07:04:00 +00:00

Findings from a phase III study in patients recruited through the PATCH and STAMPEDE-1 trial networks

EMA Recommends Extension of Indications for Selpercatinib

noreply@esmo.org — Wed, 15 Apr 2026 07:04:00 +00:00

New indications concern extension from adolescents to the treatment of paediatric patients 2 years of age and older with advanced thyroid cancer with RET alterations and treatment of advanced solid tumours with RET fusion

Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

noreply@esmo.org — Tue, 14 Apr 2026 13:04:00 +00:00

New systemic and local treatment options re-shape algorithms for the treatment of metastatic colorectal cancer: the updated ESMO Clinical Practice Guideline.

OS Advantage of Gotistobart Over Docetaxel in Patients with anti-PD‑(L)1- and Chemotherapy-Resistant Metastatic Squamous NSCLC

noreply@esmo.org — Tue, 14 Apr 2026 07:04:00 +00:00

Findings from the stage 1 of the phase III PRESERVE-003 study

Safety and Antitumour Activity of Setidegrasib in Patients with Previously Treated Advanced KRAS p.G12D-mutated NSCLC and PADC

noreply@esmo.org — Mon, 13 Apr 2026 07:04:00 +00:00

Findings from a first-in-human phase I study

EMA Recommends Granting a Marketing Authorisation for Poherdy

noreply@esmo.org — Fri, 10 Apr 2026 07:04:00 +00:00

It is a biosimilar of pertuzumab which was authorised in the EU in 2013

Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers

noreply@esmo.org — Thu, 09 Apr 2026 07:04:00 +00:00

Findings from the real-world study conducted by the Netherlands Cancer Institute